Drug for thrombocytopenia

Share This Post

Dova Pharmaceuticals said that the US Food and Drug Administration (FDA) approved its subsidiary AkaRx’s new drug Doptelet (avatrombopag) tablets for treating low platelet counts (thrombocytopenia) in adults with chronic liver disease (CLD) who are going to have surgery for cancer or a tooth. It is worth mentioning that this is the third new drug approved by the FDA within a week and the first drug currently approved for this purpose.

Platelets are colorless cells produced in the bone marrow that help form blood clots in blood vessels and prevent bleeding. Cancer chemotherapy usually causes thrombocytopenia.

Doptelet (avatrombopag) is the second generation, once-daily oral thrombopoietin (TPO) receptor agonist. Doptelet can mimic the effect of TPO, it is the main regulator of normal platelet production. The drug has received priority review qualifications to treat thrombocytopenia in adults with CLD who will undergo surgery.

Doptelet’s safety and effectiveness were verified in two trials (ADAPT-1 and ADAPT-2). These studies included a total of 435 patients with chronic liver disease and severe thrombocytopenia, who will undergo surgery that usually requires platelet transfusions. These trials evaluated the effect of oral doptelet at two dose levels compared to placebo for 5 days of treatment. The results showed that compared with the placebo group, a higher percentage of patients in the two-dose level Doptelet group had increased platelet counts and did not need to receive platelet transfusion or any rescue treatment on the day of surgery and within 7 days after treatment. The most common side effects of Doptelet are fever, stomach (abdominal) pain, nausea, headache, fatigue, and swelling of hands and feet (edema).

“Patients with low platelet counts and chronic liver disease requiring surgery have an increased risk of bleeding,” said Dr. Richard Pazdur, director of the Center for Excellence in Oncology and the acting director of the Office of Hematology and Oncology Products at the FDA Center for Drug Evaluation and Research. Increase the platelet count. This drug may reduce or eliminate the need for platelet transfusion, (platelet transfusion) may increase the risk of infection and other adverse reactions.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy